Analysis of tumor recurrence factors of the patients with intermediate risk papillary thyroid carcinoma after radioactive iodine treatment

Objective To analyze the recurrence factors of the patients with intermediate risk papillary thyroid carcinoma (PTC) after radioactive iodine treatment (RAIT). Methods A total of 254 intermediate risk PTC patients after RAIT from January 2018 to May 2020 in our hospital were enrolled into this study...

Full description

Bibliographic Details
Main Author: TANG Linglin, LI Li, LAI Yi, LIU Jianjun, ZHOU Xiang
Format: Article
Language:zho
Published: Editorial Office of Journal of Surgery Concepts & Practice 2023-11-01
Series:Waike lilun yu shijian
Subjects:
Online Access:https://www.qk.sjtu.edu.cn/jscp/fileup/1007-9610/PDF/1709530009390-1767440910.pdf
_version_ 1797279077593251840
author TANG Linglin, LI Li, LAI Yi, LIU Jianjun, ZHOU Xiang
author_facet TANG Linglin, LI Li, LAI Yi, LIU Jianjun, ZHOU Xiang
author_sort TANG Linglin, LI Li, LAI Yi, LIU Jianjun, ZHOU Xiang
collection DOAJ
description Objective To analyze the recurrence factors of the patients with intermediate risk papillary thyroid carcinoma (PTC) after radioactive iodine treatment (RAIT). Methods A total of 254 intermediate risk PTC patients after RAIT from January 2018 to May 2020 in our hospital were enrolled into this study. Chi square test and multivariate analysis were applied to analyze the main recurrence factors after RAIT. Results Thirty four (13.4%) patients with intermediate risk PTC relapsed after RAIT. The primary tumor size, lymph node metastasis staging, and pre-ablation stimulated thyroglobulin (psTg) were associated with tumor recurrence. According to the receiver operating characteristic (ROC) curve, psTg 25.6 μg/L was the best cutoff value for predicting recurrence. Further multivariate analysis revealed that lymph node metastasis staging and psTg levels were independent factors of predicting PTC recurrence. When the patients with N1b and psTg≥25.6 μg/L, the incidence of tumor recurrence after RAIT was 58.3%. While the patients with N1a and psTg<25.6 μg/L, the incidengce of tumor recurrence was only 2.3%. Conclusions Lymph node metastasis staging and psTg level are the important indicators of PTC recurrence, and combining these two indicators can help predict tumor recurrence after RAIT.
first_indexed 2024-03-07T16:18:09Z
format Article
id doaj.art-b2883c52e47046db8510624149110632
institution Directory Open Access Journal
issn 1007-9610
language zho
last_indexed 2024-03-07T16:18:09Z
publishDate 2023-11-01
publisher Editorial Office of Journal of Surgery Concepts & Practice
record_format Article
series Waike lilun yu shijian
spelling doaj.art-b2883c52e47046db85106241491106322024-03-04T09:43:53ZzhoEditorial Office of Journal of Surgery Concepts & PracticeWaike lilun yu shijian1007-96102023-11-01280653653910.16139/j.1007-9610.2023.06.09Analysis of tumor recurrence factors of the patients with intermediate risk papillary thyroid carcinoma after radioactive iodine treatmentTANG Linglin, LI Li, LAI Yi, LIU Jianjun, ZHOU Xiang0a. Department of Nuclear Medicine, Renji Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai 200127, China;b. Department of Head and Neck Surgery, Renji Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai 200127, ChinaObjective To analyze the recurrence factors of the patients with intermediate risk papillary thyroid carcinoma (PTC) after radioactive iodine treatment (RAIT). Methods A total of 254 intermediate risk PTC patients after RAIT from January 2018 to May 2020 in our hospital were enrolled into this study. Chi square test and multivariate analysis were applied to analyze the main recurrence factors after RAIT. Results Thirty four (13.4%) patients with intermediate risk PTC relapsed after RAIT. The primary tumor size, lymph node metastasis staging, and pre-ablation stimulated thyroglobulin (psTg) were associated with tumor recurrence. According to the receiver operating characteristic (ROC) curve, psTg 25.6 μg/L was the best cutoff value for predicting recurrence. Further multivariate analysis revealed that lymph node metastasis staging and psTg levels were independent factors of predicting PTC recurrence. When the patients with N1b and psTg≥25.6 μg/L, the incidence of tumor recurrence after RAIT was 58.3%. While the patients with N1a and psTg<25.6 μg/L, the incidengce of tumor recurrence was only 2.3%. Conclusions Lymph node metastasis staging and psTg level are the important indicators of PTC recurrence, and combining these two indicators can help predict tumor recurrence after RAIT.https://www.qk.sjtu.edu.cn/jscp/fileup/1007-9610/PDF/1709530009390-1767440910.pdf|papillary thyroid carcinoma|intermediate risk|radioactive iodine treatment|tumor recurrence|thyroglobulin
spellingShingle TANG Linglin, LI Li, LAI Yi, LIU Jianjun, ZHOU Xiang
Analysis of tumor recurrence factors of the patients with intermediate risk papillary thyroid carcinoma after radioactive iodine treatment
Waike lilun yu shijian
|papillary thyroid carcinoma|intermediate risk|radioactive iodine treatment|tumor recurrence|thyroglobulin
title Analysis of tumor recurrence factors of the patients with intermediate risk papillary thyroid carcinoma after radioactive iodine treatment
title_full Analysis of tumor recurrence factors of the patients with intermediate risk papillary thyroid carcinoma after radioactive iodine treatment
title_fullStr Analysis of tumor recurrence factors of the patients with intermediate risk papillary thyroid carcinoma after radioactive iodine treatment
title_full_unstemmed Analysis of tumor recurrence factors of the patients with intermediate risk papillary thyroid carcinoma after radioactive iodine treatment
title_short Analysis of tumor recurrence factors of the patients with intermediate risk papillary thyroid carcinoma after radioactive iodine treatment
title_sort analysis of tumor recurrence factors of the patients with intermediate risk papillary thyroid carcinoma after radioactive iodine treatment
topic |papillary thyroid carcinoma|intermediate risk|radioactive iodine treatment|tumor recurrence|thyroglobulin
url https://www.qk.sjtu.edu.cn/jscp/fileup/1007-9610/PDF/1709530009390-1767440910.pdf
work_keys_str_mv AT tanglinglinlililaiyiliujianjunzhouxiang analysisoftumorrecurrencefactorsofthepatientswithintermediateriskpapillarythyroidcarcinomaafterradioactiveiodinetreatment